The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Preclinical models and clinical data suggest differential drug sensitivities for different EGFR exon 19 indels, with the rarer EGFR L747_A750delinsP mutation showing reduced sensitivity to erlotinib & osimertinib but high sensitivity to afatinib.